These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 27761964)

  • 1. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.
    Mahlangu JN; Andreeva TA; Macfarlane DE; Walsh C; Key NS
    Haemophilia; 2017 Jan; 23(1):33-41. PubMed ID: 27761964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
    Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
    Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A.
    Fosbury E; Drebes A; Riddell A; Chowdary P
    Ther Adv Hematol; 2017 Sep; 8(9):263-272. PubMed ID: 29051804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors.
    Rubinger M; Houston DS; Schwetz N; Woloschuk DM; Israels SJ; Johnston JB
    Am J Hematol; 1997 Oct; 56(2):112-8. PubMed ID: 9326353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion of porcine factor VIII in patients with haemophilia A and high-responding inhibitors: stability and clinical experience.
    O'Gorman P; Dimichele DM; Kasper CK; Mannucci PM; Santagostini E; Hay CR
    Haemophilia; 2001 Nov; 7(6):537-43. PubMed ID: 11851750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A.
    Gomperts E
    Expert Rev Hematol; 2015 Aug; 8(4):427-32. PubMed ID: 25927594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susoctocog Alfa: A Review in Acquired Haemophilia A.
    Burness CB; Scott LJ
    Drugs; 2016 May; 76(7):815-21. PubMed ID: 27098420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
    Kruse-Jarres R; St-Louis J; Greist A; Shapiro A; Smith H; Chowdary P; Drebes A; Gomperts E; Bourgeois C; Mo M; Novack A; Farin H; Ewenstein B
    Haemophilia; 2015 Mar; 21(2):162-170. PubMed ID: 25623166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitor development against FVIII in previously treated patients with haemophilia A. A retrospective data collection].
    Siegmund B; Pollmann H; Richter H; Orlovic M; Gottstein S; Klamroth R
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S37-9. PubMed ID: 21042673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.
    van Velzen AS; Eckhardt CL; Streefkerk N; Peters M; Hart DP; Hamulyak K; Klamroth R; Meijer K; Nijziel M; Schinco P; Yee TT; van der Bom JG; Fijnvandraat K;
    Thromb Haemost; 2016 Mar; 115(3):543-50. PubMed ID: 26582077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.
    Mannucci PM; Franchini M
    Blood Transfus; 2017 Jul; 15(4):365-368. PubMed ID: 27483484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients.
    Tarantino MD; Cuker A; Hardesty B; Roberts JC; Sholzberg M
    Haemophilia; 2017 Jan; 23(1):25-32. PubMed ID: 27511890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.
    Lloyd Jones M; Wight J; Paisley S; Knight C
    Haemophilia; 2003 Jul; 9(4):464-520. PubMed ID: 12828680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Porcine factor VIII in the treatment of high-titre inhibitor patients.
    Garvey MB
    Haemophilia; 2002 Jan; 8 Suppl 1():5-8; discussion 28-32. PubMed ID: 11882075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.